Researchers led by J Petersen and Christoffer Clemmensen at the University of Copenhagen report results from pairing the two obesity drugs. Full findings are in the paper.
Recap by typeshit. Post by Nature Metabolism on X.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
Employers pick their own contribution toward semaglutide shots or pills. AJMC notes WTW found GLP-1 weight loss coverage fell to 53% of employers, the first drop in three years.
The listener was on a microdose. Dr. Cole says the scientific literature shows no established link between semaglutide and the finding, per @theartofbeingwell_.
Loading…